Endo Pharmaceuticals Holdings Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).

Endo Pharmaceuticals Holdings Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For quarter, the company reported total revenues of $361,027,000, operating income of $84,314,000, income before income taxes of $79,329,000, net income of $49,422,000 or $0.42 diluted per share compared with total revenues of $316,768,000, operating income of $107,327,000, income before income taxes of $105,917,000, net income of $65,994,000 or $0.55 diluted per share over the same period last year. Adjusted total revenues were $361,027,000, adjusted operating income was $386,447,000, adjusted income before income taxes was $115,010,000, adjusted net income of $74,251,000 or $0.63 diluted per share compared with adjusted total revenues of $316,768,000, adjusted operating income of $124,339,000, adjusted income before income taxes of $126,540,000, adjusted net income of $78,724,000 or $0.66 diluted per share over the same period last year. For nine months, the company reported total revenues of $1,069,435,000, operating income of $226,696,000, income before income taxes of $204,112,000, net income of $118,488,000 or $1.01 diluted per share, net cash provided by operating activities of $219,015,000 compared with total revenues of $913,200,000,operating income of $274,544,000, income before income taxes of $283,671,000, net income of $182,650,000 or $1.45 diluted per share, net cash provided by operating activities of $228,109,000 over the same period last year. Adjusted total revenues of $1,069,435,000, adjusted operating income of $386,447,000, adjusted income before income taxes of $368,532,000, adjusted net income of $239,141,000 or $2.04 diluted per share compared with adjusted total revenues of $913,200,000, adjusted operating income of $327,543,000, adjusted income before income taxes of $343,290,000, adjusted net income of $219,638,000 or $1.74 diluted per share over the same period last year. The company provided earnings guidance for the full year ending December 31, 2009. For the period the company estimates total revenues to be between $1.440 billion and $1.465 billion. The company also now estimates reported (GAAP) diluted earnings per share to be between $1.41 and $1.47, and this EPS increase is primarily due to changes in the fair value of contingent consideration associated with the Indevus transaction partially offset by the addition of milestone payments associated with the company's recent deal with ProStrakan to in-license FORTESTA(TM). Adjusted diluted earnings per share are now estimated to be between $2.67 and $2.73.

Endo Pharmaceuticals Holdings Inc. revised earnings guidance for 2009. The company will deliver 2009 total revenues of between $1.44 billion and $1.465 billion, an increase versus previous guidance of $1.39 billion to $1.44 billion. The new range reflects solid sustained performance from the core business. The company raising the guidance for adjusted diluted earnings per share to a range of $2.67 to $2.73, an increase versus previous guidance for adjusted diluted earnings per share of between $2.59 to $2.67. Reported or GAAP diluted earnings per share is now expected to fall within the range of $1.41 to $1.47, an increase versus previous guidance for GAAP earnings of $1.26 to $1.34.